OA12056A - Use of the NN'dibenzylthiourea compound as a medicament - Google Patents
Use of the NN'dibenzylthiourea compound as a medicament Download PDFInfo
- Publication number
- OA12056A OA12056A OA1200200099A OA1200200099A OA12056A OA 12056 A OA12056 A OA 12056A OA 1200200099 A OA1200200099 A OA 1200200099A OA 1200200099 A OA1200200099 A OA 1200200099A OA 12056 A OA12056 A OA 12056A
- Authority
- OA
- OAPI
- Prior art keywords
- hydroxyl radical
- human
- treatment
- diseases
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
1 2056.1 2056.
La présente invention est relative à l'utilisation de N'N DIBENZYLTHIOUREE,compose extrait du PENTADEPLANDRA BRAZZEANA variété BRAZZEANAdans le traitement thérapeutique de l'homme ou de l'animal.The present invention relates to the use of N'N DIBENZYLTHIOUREE, compound extracted from PENTADEPLANDRA BRAZZEANA variety BRAZZEANAdans the therapeutic treatment of humans or animals.
INDICATIONS THERAPEUTIQUES -........ .. .. - - ,THERAPEUTIC INDICATIONS -........ .. .. - - ,
Ce médicament est indiqué dans le traitement de toutes les maladi.es dues à laprésence du radical libre oxygénée ( radical hydroxyl : OH°) dans l'organismehumain ou animal, notamment : Maladie D'ALSHEIMER, Maladie dePARKINSON, Cancer des personnes du 3eme âge et de l’enfant, Avitaminoses'sévères chez l'adulte et enfant (kwashiorkor), Maladie cardrovasculaire, Diabète etcomplications, Vieillissement de l'organisme, Maladies dues au tabagisme.This medicinal product is indicated for the treatment of all diseases caused by the presence of the oxygenated free radical (hydroxyl radical: OH °) in the human or animal organism, in particular: ALSHEIMER'S DISEASE, PARKINSON'S DISEASE, Cancer of the elderly and children, Vitamin A deficiency in adults and children (kwashiorkor), Cardrovascular disease, Diabetes and complications, Aging of the body, Diseases caused by smoking.
Le radical hydroxyl OH° est responsable de l'altération de l'état et du fonctionnement de nombreuses cellules. 11 entraîne la dégénérescence des cellules indépendamment de leur appartenance.Jusqu'à ce jour les médicaments utilisés dans la thérapeutique de ces maladiesétaient destinés à combattre uniquement leurs symptômes. C'est ainsi qu'on utilise les dopaminergiques (apomorphine), les tranquillisants, lessomnifères, les antidépresseurs, les neuroleptiques, les oxygénateurs,vasodilatateurs.The hydroxyl radical OH ° is responsible for the alteration of the state and the functioning of many cells. It induces the degeneration of cells irrespective of their membership. Until now the drugs used in the treatment of these diseases were intended to combat only their symptoms. Thus dopaminergics (apomorphine), tranquillizers, lesser substances, antidepressants, neuroleptics, oxygenators and vasodilators are used.
Le traitement par la N'N DIBENZYLTHIOUREE est destiné à débarrasser,l'organisme du radical hydroxyl (OH°). Ce traitement préventif et curatif régénèreles tissus morts et rétablit le fonctionnement normal des cellules. ·Treatment with N'N DIBENZYLTHIOUREE is intended to rid the body of the hydroxyl radical (OH °). This preventive and curative treatment regenerates dead tissue and restores normal cell function. ·
Les radicaux libres sont des atomes, des groupes d'atomes, ou des moléculespossédant un électron non apparié ou célibataire sur l'orbital externe . La tendanceà apparier cet électron orbital externe explique leur agressivité biologique.Free radicals are atoms, groups of atoms, or molecules with an unpaired or single electron on the outer orbital. The tendency to match this external orbital electron explains their biological aggressivity.
En effet, en arrachant cet électron à une autre molécule, dès lors transformé à sontour en radical libre, ils provoquent des réactions en chaîne aboutissant àl'altération de nombreuses structures cellulaires. L'apparition du radical hydroxyl dans l'organisme se passe tle la rrianière suivante :L'eau oxygénée apparaît naturellement dans l'organisme mais elle estrégulièrement détruite par la catalase, de sorte que la réaction de formation decette eau oxygénée à partir de l'eau et de l'oxygène est réversible. H2O2 ' <.....— H2O + Ά O2 (sous l'action de la catalase). * · 1 1 2056Indeed, by tearing this electron to another molecule, since then converted to estour free radical, they cause chain reactions leading to the alteration of many cell structures. The appearance of the hydroxyl radical in the organism occurs in the following way: Hydrogen peroxide appears naturally in the organism but it is regularly destroyed by catalase, so that the reaction of formation of this oxygenated water from the water and oxygen is reversible. H2O2 '<.....- H2O + Ά O2 (under the action of catalase). * 1 1 2056
Chez l'enfant de 0 à 5 ans et personne âgée on constate, une insuffisance de lasécrétion de la catalase et la réaction ci-dessus n'est plus réversible - l'eauoxygénée subit la réaction, de fenton au cours de laquelle il se décompose en un 'banal ion OH" et un radical hydroxyl OH° très réactif. .. AIn the child of 0 to 5 years old and senior, there is a deficiency of catalase secretion and the above reaction is no longer reversible - the oxygenated water undergoes the reaction, fenton during which it decomposes into a "common OH ion" and a hydroxyl radical OH ° very reactive.
Cette réaction se fait en présence de Fe2+ présent dans l'organisme humain ou.animal .This reaction is in the presence of Fe2 + present in the human or animal organism.
Fe2+ + H2O2->Fe3+ + ΟΗΓ + OH° L'apparition radical OH° dans l'organisme peut aussi être induite directement parla chaleur, la lumière ou radiation énergétique. L'altération de nombreusesstructures cellulaires porte généralement sur les noyaux : modification desstructures des éléments nobles particulièrement des acides ribonucléiques etdésoxyribonucléiques ainsi que sur les doubles liaisons des acides gras polyinsaturés de la membrane cellulaire.Fe2 + + H2O2-> Fe3 + + ΟΗΓ + OH ° The OH ° radical appearance in the body can also be directly induced by heat, light or energetic radiation. The alteration of many cellular structures is generally related to the nuclei: modification of the structures of noble elements, particularly of ribonucleic and deoxyribonucleic acids, as well as on the double bonds of the polyunsaturated fatty acids of the cell membrane.
Les maladies constituant les indications thérapeutiques chez l'homme ou chezl'animal de la NN' DIBENZYLTHIOUREE sont provoquées dans l'organismepar l'agressivité du radical hydroxyl.The diseases constituting the therapeutic indications in man or in the animal of NN 'DIBENZYLTHIOUREE are caused in the body by the aggressivity of the hydroxyl radical.
La lutte contre ces maladies consiste en l'utilisation des molécules biologiques-pouvant donner un atome d'hydrogène au radical hydroxyl. Pour le transformer eneau (H2O). Par exemple : la NN’ DIBENZILTHIOUREE donne les H mobiles ouhydrogènes mobiles au radical hydroxyl selon le mécanisme suivant :The fight against these diseases consists of the use of biological molecules that can give a hydrogen atom to the hydroxyl radical. To transform it into water (H2O). For example: NN 'DIBENZILTHIOUREE gives the mobile H or mobile hydrogen to the hydroxyl radical according to the following mechanism:
S +4HO°S + 4HO °
POLYMEREPOLYMER
STABLESTABLE
Le médicament, objet de la présente invention ayant poqr principe actif la NN’DIBENZILTHIOUREE extraite du PENTAPLANDRA BRAZZEANAVARIETE BRAZZEANA fournit les "H" au radical hydroxyl OH°, le 2 1 2056 transformant ainsi en eau (H2O) qui s'élimine de l'organisme par voie urinaire et lepolymère formé qui est neutre s'élimine aussi par voie urinaire. ? L'avantage de cet antioxydant est qu'il est biologique. * 5 La NN' DIBENZYTHIOUREE n'est pas toxique à part son action ocytocique sur l'utérus gravide.The medicinal product which is the subject of the present invention having the active ingredient NN'DIBENZILTHIOUREE extracted from PENTAPLANDRA BRAZZEANAVARIETE BRAZZEANA supplies the "H" to the hydroxyl radical OH °, thereby transforming it into water (H2O) which is eliminated from the urinary organism and the formed polymer which is neutral is also eliminated by the urinary tract. ? The advantage of this antioxidant is that it is organic. * 5 NN 'DIBENZYTHIOUREE is not toxic apart from its oxytocic action on the pregnant uterus.
Ce médicament est présenté sous les formes galéniques suivantes : 10 SiropThis medicine is presented in the following dosage forms: 10 Syrup
COMPOSITION - NN' DIBENZYL THIOUREE 108 mg 15 Excipient : sirop saccharose QSP 250 mlCOMPOSITION - NN 'DIBENZYL THIOUREE 108 mg 15 Excipient: syrup sucrose QSP 250 ml
POSOLOGIE ADULTE : 2 cuillerées à soupe Matin et soir 20 ' · ENFANT : 2 cuillerées à café Matin et soir D'autres formes par voie orale (gélules, comprimés) et voie rectale (suppositoire)peuvent être fabriquées. Il faut simplement protéger la NN' 25 DIBENZYLTHIOUREE contre l'oxygène de l'air. 3ADULT DOSAGE: 2 tablespoons Morning and evening 20 '· CHILD: 2 teaspoons Morning and evening Other oral forms (capsules, tablets) and rectal route (suppository) can be made. It is simply necessary to protect the NN 'DIBENZYLTHIOUREE against the oxygen of the air. 3
Claims (3)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
OA1200200099A OA12056A (en) | 2002-04-05 | 2002-04-05 | Use of the NN'dibenzylthiourea compound as a medicament |
PCT/OA2003/000002 WO2003084523A1 (en) | 2002-04-05 | 2003-03-27 | Use of a n,n'-dibenzyl-thiourea as medicine |
AU2003232698A AU2003232698A1 (en) | 2002-04-05 | 2003-03-27 | Use of a n,n'-dibenzyl-thiourea as medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
OA1200200099A OA12056A (en) | 2002-04-05 | 2002-04-05 | Use of the NN'dibenzylthiourea compound as a medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12056A true OA12056A (en) | 2003-10-24 |
Family
ID=34102066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200099A OA12056A (en) | 2002-04-05 | 2002-04-05 | Use of the NN'dibenzylthiourea compound as a medicament |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003232698A1 (en) |
OA (1) | OA12056A (en) |
WO (1) | WO2003084523A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009042693A1 (en) * | 2009-09-23 | 2011-03-24 | Merck Patent Gmbh | Materials for electronic devices |
FR2988000A1 (en) * | 2012-03-16 | 2013-09-20 | Thomas Wandji | Combination of propylene methoxy-4-phenyl-2-methyl-2-isothiocyanate, N,N-dibenzylthiourea in the form of hydroalcoholic solution (anti oxidant), beta-sitosterol and stigmasterol as an antiviral drug, for killing human and animal viruses |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2166349A1 (en) * | 1972-01-04 | 1973-08-17 | Wandji Thomas | Difeu alkaloids - for treating diarrhoea, peptic ulcer anorexia, as a diuretic, as a sclerosing agent |
FR2693106A1 (en) * | 1992-10-02 | 1994-01-07 | Wandji Thomas | Extract contg. aromatic isothiocyanate, thiocarbamate, and thiourea - for the treatment of functional metrorrhagia, and as a venous tonic and free radical trap |
-
2002
- 2002-04-05 OA OA1200200099A patent/OA12056A/en unknown
-
2003
- 2003-03-27 WO PCT/OA2003/000002 patent/WO2003084523A1/en not_active Application Discontinuation
- 2003-03-27 AU AU2003232698A patent/AU2003232698A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003232698A1 (en) | 2003-10-20 |
WO2003084523A1 (en) | 2003-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Holdiness | Clinical pharmacokinetics of N-acetylcysteine | |
Prescott et al. | Successful treatment of severe paracetamol overdosage with cysteamine | |
KR100245482B1 (en) | Active oxygen scavenger | |
Emerit et al. | Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease | |
JP2006515290A (en) | Witania somnifera composition, method for obtaining it, and pharmaceutical formulations, nutritional agents and personal care formulations thereof | |
FR2508798A1 (en) | ANTHRAQUINONIC DERIVATIVES FOR THE TREATMENT OF ARTHRITIS | |
CA2802154C (en) | A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof | |
JP2001064192A (en) | Migration inhibitor for langerhans cell and antigen presentation inhibitor | |
JPH0714867B2 (en) | Pharmaceutical composition for suppressing aging | |
EP1464330B1 (en) | antiallergic composition containing oligosaccharides in combination with a saponine or a basic aminoacid, for topical administration or for inhalation | |
Li et al. | Lipoic acid protects gastric mucosa from ethanol-induced injury in rat through a mechanism involving aldehyde dehydrogenase 2 activation | |
Jung et al. | Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis | |
OA12056A (en) | Use of the NN'dibenzylthiourea compound as a medicament | |
KR20010082721A (en) | Fatty-acid containing composition | |
Briffa et al. | Photochemotherapy in psoriasis: a review | |
KR102152407B1 (en) | Cosmetic composition containing phycocyanobilin and its derivative derived from spirulina | |
US20060058392A1 (en) | Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase | |
RU2556962C1 (en) | Method of treating chronic opisthorchiasis in patients with rosacea | |
JP7542055B2 (en) | Inhibitor of degradation of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafin complex, and composition containing the same | |
JP3533231B2 (en) | Alcohol absorption inhibitor | |
JPS58501911A (en) | Rheumatoid arthritis treatment drug | |
WO2017137767A1 (en) | Anti-neurodegenerative disease formulation containing apocynin and paeonol | |
US20060167104A1 (en) | Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family and use of N,N'-dibenzylthiourea as a medicine | |
Panda et al. | Zinc in Ayurvedic herbo-mineral products | |
Alphin | Archive of SID. ir |